NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19

https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19

The interim analysis of results from the trial (known as the Adaptive COVID-19 Treatment Trial, or ACTT), sponsored by the   National Institute of Allergy and Infectious Diseases (NIAID) suggest that remdesivir had a 31% faster time to recovery than those who received placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0% for the group receiving remdesivir versus 11.6% for the placebo group (p=0.059). 

Tags: